ERBB2 and breast cancer: A pooled analysis by the Food and Drug Administration (FDA) [19] indicated that all clinicopathological subgroups of patients with HR-positive, HER2-negative advanced BC derived benefits from CDK4/6 inhibitors, irrespective of PgR expression.